Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4OZC7
|
|||
| Drug Name |
Suvodirsen
|
|||
| Synonyms |
WVE-210201
Click to Show/Hide
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Duchenne dystrophy [ICD-11: 8C70; ICD-10: G71.0] | Phase 2/3 | [1] | |
| Company |
Wave Life Sciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dystrophin messenger RNA (DMD mRNA) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Hypertrophic cardiomyopathy (HCM) | |||
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ||||
| Dilated cardiomyopathy | ||||
| Viral myocarditis | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| IL5 Signaling Pathway | ||||
| Reactome | Non-integrin membrane-ECM interactions | |||
| Striated Muscle Contraction | ||||
| WikiPathways | Striated Muscle Contraction | |||
| Ectoderm Differentiation | ||||
| Extracellular matrix organization | ||||
| Arrhythmogenic Right Ventricular Cardiomyopathy | ||||
| Muscle contraction | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03907072) Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51). U.S. National Institutes of Health. | |||
| REF 2 | Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.